Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma

ŠKODA, Jan, Markéta HERMANOVÁ, Tomáš LOJA, Pavel NĚMEC, Jakub NERADIL, Petr KARÁSEK and Renata VESELSKÁ. Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. PLOS One. San Francisco: PUBLIC LIBRARY SCIENCE, vol. 11, No 7, p. "e0159255", 18 pp. ISSN 1932-6203. doi:10.1371/journal.pone.0159255. 2016.

Basic information

• Original name: Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma
• Authors: ŠKODA, Jan (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Tomáš LOJA (703 Slovakia, belonging to the institution), Pavel NĚMEC (203 Czech Republic, belonging to the institution), Jakub NERADIL (203 Czech Republic, belonging to the institution), Petr KARÁSEK (203 Czech Republic) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: PLOS One, San Francisco, PUBLIC LIBRARY SCIENCE, 2016, 1932-6203.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.806
• RIV identification code: RIV/00216224:14310/16:00095874
• Organization unit: Faculty of Science
• Doi: http://dx.doi.org/10.1371/journal.pone.0159255
• UT WoS: 000379579500112
• Keywords in English: pancreatic adenocarcinoma;cancer stem cell markers;expression profilimg
• Tags: EL OK, NZ, podil, rivok
• Tags: International impact, Reviewed

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Its dismal prognosis is often attributed to the presence of cancer stem cells (CSCs) that have been identified in PDAC using various markers. However, the co-expression of all of these markers has not yet been evaluated. Furthermore, studies that compare the expression levels of CSC markers in PDAC tumor samples and in cell lines derived directly from those tumors are lacking. Here, we analyzed the expression of putative CSC markers-CD24, CD44, epithelial cell adhesion molecule (EpCAM), CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 PDAC-derived cell lines and by immunohistochemistry in 3 corresponding tumor samples. We showed high expression of the examined CSC markers among all of the cell lines and tumor samples, with the exception of CD24 and CD44, which were enriched under in vitro conditions compared with tumor tissues. The proportions of cells positive for the remaining markers were comparable to those detected in the corresponding tumors. Co-expression analysis using flow cytometry revealed that CD24+/CD44+/EpCAM+/CD133+ cells represented a significant population of the cells (range, 43 to 72%) among the cell lines. The highest proportion of CD24+/CD44+/EpCAM+/CD133+ cells was detected in the cell line derived from the tumor of a patient with the shortest survival. Using gene expression profiling, we further identified the specific pro-tumorigenic expression profile of this cell line compared with the profiles of the other two cell lines. Together, CD24+/CD44+/EpCAM+/CD133+ cells are present in PDAC cell lines derived from primary tumors, and their increased proportion corresponds with a pro-tumorigenic gene expression profile.

Links

• EE2.3.20.0183, research and development project: Name: Centrum experimentální biomedicíny